Rivaroxaban is reimbursed.
Rivaroxaban belongs to Category B of medical insurance. The expenses incurred by using this type of drug will be paid by the insured at a certain proportion first, and then included in the scope of payment of the basic medical insurance fund, and will be paid according to the basic medical insurance. payment of fees.
The medical expenses incurred after the insured person is transferred to another hospital shall be paid by the individual or unit in advance in cash. After the medical treatment is completed, the insured person or his agent shall hold the transfer approval form, medical record certificate, Bring prescriptions and valid documents to the medical insurance agency for reimbursement of hospitalization expenses that fall within the scope of payment by the unified fund.
The drugs reimbursed by medical insurance are specific. Only drugs in the medical insurance catalog can be reimbursed, but drugs outside the medical insurance catalog cannot be reimbursed, such as many imported and expensive innovative drugs and patented drugs. Therefore, communicate with your doctor before taking medicine. If you want to save money, you should use the medicines in the catalog.
Legal Basis
Article 28 of the "Interim Measures for the Administration of Drug Use under Basic Medical Insurance": Designated medical institutions should improve their organizational structure, improve internal systems and regulations, and establish and improve the "import and sales" of drugs. ", deposit" full-process record and management system to improve medical insurance medication management capabilities and ensure the safety and rationality of medical insurance medication.
Article 29 of the "Interim Measures for the Administration of Drug Use under Basic Medical Insurance" incorporates the "Drug Catalog" and related policy implementation responsibilities into the agreement of designated medical institutions, strengthens the rationality and cost review of drug use, and carries out regular supervision and inspection . Link the medical insurance drug preparation rate and non-medical insurance drug utilization rate to the fund payment of designated medical institutions. Strengthen the supervision and inspection of designated medical institutions to implement medical insurance drug management policies and perform their responsibilities in drug preparation, use, payment, and management.